Novo Nordisk’s Victoza gets FDA okay for paediatric useNovo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as Share XNovo Nordisk’s Victoza gets FDA okay for paediatric usehttps://pharmaphorum.com/news/novo-nordisks-victoza-fda-paediatric-use/
Novo Nordisk builds cardio claim case for oral semaglutideNovo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has Share XNovo Nordisk builds cardio claim case for oral semaglutidehttps://pharmaphorum.com/news/novo-nordisk-builds-cardio-claim-case-for-oral-semaglutide/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseaseAfter moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on Share XBeyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney diseasehttps://pharmaphorum.com/r-d/views-analysis-r-d/beyond-glucose-in-type-2-diabetes-how-novo-nordisk-is-looking-to-address-chronic-kidney-disease/
Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorsA new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group Share XSanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorshttps://pharmaphorum.com/news/sanofi-regeneron-skin-cancer-drug-among-flurry-of-approvals-from-eu-regulators/
FDA approves PureTech’s obesity device PlenityThe FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting Share XFDA approves PureTech’s obesity device Plenityhttps://pharmaphorum.com/news/fda-approves-puretech-obesity-plenity/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Novo Nordisk and Abbott announce digital diabetes tie-upNovo Nordisk and devices firm Abbott have announced a partnership that aims to make diabetes management easier by Share XNovo Nordisk and Abbott announce digital diabetes tie-uphttps://pharmaphorum.com/news/novo-nordisk-and-abbott-announced-digital-diabetes-tie-up/
